|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
ASCO Weekend Recap: OncoGenex, Seattle Genetics, Vulcan-Backed BiPar Show Off Cancer Drug Results
|
Luke Timmerman |
06/01/09 |
Seattle
|
|
Seattle Genetics “Empowered Antibody” Wipes Out Hodgkin’s Tumors in Early Study
|
Luke Timmerman |
06/01/09 |
Seattle
|
|
Why Should the Public Care About Biotech? Why is the Answer Always Jobs?
|
Luke Timmerman |
04/24/09 |
Seattle
|
|
Genzyme Enters Seattle Hub, Oncothyreon Bets on Cancer Drugs, Pathway Nabs $40M, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
04/02/09 |
Seattle
|
|
Seattle Genetics Gets Fast Track
|
Luke Timmerman |
03/30/09 |
Seattle
|
|
Souped-Up Herceptin Aims to Validate ImmunoGen’s Long-Sought Dream Cancer Drug
|
Luke Timmerman |
03/06/09 |
Boston
|
|
UW’s Gardasil Windfall, Cell Therapeutics Unloads Zevalin, Trubion Cuts Jobs, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
02/26/09 |
Seattle
|
|
Seattle Genetics Starts Pivotal Trial
|
Luke Timmerman |
02/19/09 |
Seattle
|
|
Seattle Genetics Defies Gravity With Biotech’s First Underwritten Stock Sale in Six Months
|
Luke Timmerman |
02/05/09 |
Seattle
|
|
Seattle Genetics Raises $55M
|
Luke Timmerman |
01/28/09 |
Seattle
|
|
Seattle Genetics Gets Orphan Drug Status
|
Luke Timmerman |
01/26/09 |
Seattle
|
|
Dendreon Expects Results in April, Seattle Genetics Plans Hodgkin’s Trial, ImaRx Moves to Town & More Seattle-Area Life Sciences News
|
Luke Timmerman |
01/22/09 |
Seattle
|
|
Seattle Genetics Unveils Pivotal Trial Plan for “Empowered Antibody”
|
Luke Timmerman |
01/21/09 |
Seattle
|
|
Seattle Genetics Drug Fights Hodgkin’s, Frazier Sounds Off on Biotech Ventures, SBRI Pushes Malaria Vaccine, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
12/11/08 |
Seattle
|
|
Seattle Genetics “Empowered Antibody” Shines at Blood Disease Meeting
|
Luke Timmerman |
12/06/08 |
Seattle
|
|
Seattle Genetics Hires Waller To Lead Regulatory Affairs, as SGN-35 Heads to Pivotal Trial
|
Luke Timmerman |
09/30/08 |
Seattle
|
|
Seattle Genetics’ Medical Point Man, Tom Reynolds, Aims to Capitalize on Hodgkin’s Drug
|
Luke Timmerman |
09/08/08 |
Seattle
|
|
Page 2 of
2 |
« previous page |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.